Slide 1: Advancing four drivers of growth
HY Advancing 2026 four drivers of growth July 2026, Investor webcast
Slide 2: Forward-looking statements
Forward-looking statements The information in this presentation contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as “intend”, "estimates", "believes", "expects", "may", "are expected to", "will",
Slide 3: There is significant untapped value in Idorsia
“There is significant untapped value in Idorsia.” Jean-Paul Clozel, MD, interim CEO and Chairman 3 HY 2026 Financial Reporting | July 2026
Slide 4: Strong performance in H1 2026 – well on track
Strong performance in H1 2026 – well on track New CEO appointed – Roland CHF million Wandeler to join October 1st Idorsia-led QUVIVIQ sales 200* 134 Financing of CHF 250 m from Pharmakon 61 H1 91 31 2026 Full-year 2026 2023 2024 2025 2026 guidance reaffirmed * Guidance for 2026 4 HY 2026 Financial R
Slide 5: Advancing four key drivers of growth
Advancing four key drivers of growth 1 Maximize the current QUVIVIQ® opportunity in insomnia 2 Expand the long-term value of daridorexant beyond insomnia 3 Unlock the value of TRYVIO / JERAYGO 4 Advance innovation and the pipeline Driving simultaneous initiatives to unlock substantial long-term valu
Slide 6: Maximize the current opportunity in insomnia
Maximize the current opportunity in insomnia 1 Commercial momentum 2 Expanding geographical reach 3 Expanding access to patients 4 Expanding reach into primary care 5 Reinforcing differentiation 6 HY 2026 Financial Reporting | July 2026
Slide 7: QUVIVIQ continues to reshape the insomnia treatment landscape
“QUVIVIQ continues to reshape the insomnia treatment landscape, and Idorsia is investing to accelerate its trajectory toward blockbuster status.” Benjamin Limal, Head of Europe and International Markets 7 HY 2026 Financial Reporting | July 2026
Slide 8: QUVIVIQ growth remains strong
QUVIVIQ growth remains strong EUCAN QUVIVIQ Volume (million tabs) Secure public reimbursement to expand access & improve the patient experience 34 29 Invest in specialty promotion 24 Inclusion of daytime functioning benefit – unique 18 value proposition for prescribers, patients, & payers 14 Expand
Slide 9: QUVIVIQ market share is growing
QUVIVIQ market share is growing Growth in the top 3 markets May 2026 • Insomnia is a condition primarily managed by primary 10.0% care physicians • Accelerating awareness and 7.9% adoption in primary care Co-promotion Co-promotion Co-promotion 3.1% Jan-24 Apr-24 Jul-24 Oct-24 Jan-25 Apr-25 Jul-25 Oc
Slide 10: Expanding geographical reach
Expanding geographical reach C & E Europe Negotiations ongoing Potential launch 2H 2026 Greater China Out-licenced to Simcere in 2022 • China: launched 09/25 • Hong Kong: launched 11/25 Idorsia-led Licensed Priority targets Japan & Asia Pacific Out-licenced to Nxera in 2023 • Japan: launched 09/24 p
Slide 11: Expanding access to patients
Expanding access to patients Public reimbursement Private access Out of Pocket Expansion opportunity 11 HY 2026 Financial Reporting | July 2026
Slide 12: Expanding reach into primary care
Expanding reach into primary care Co-promotion partner 12 HY 2026 Financial Reporting | July 2026
Slide 13: We can accelerate QUVIVIQ profitable growth in the US
“We can accelerate QUVIVIQ profitable growth in the US.” Shal Jacobovitz President Idorsia US 13 HY 2026 Financial Reporting | July 2026
Slide 14: US QUVIVIQ sales return to growth
US QUVIVIQ sales return to growth CHF million US QUVIVIQ sales Scalable, profitable growth model A sharper and more focused commercial 9.3 strategy balancing near-term execution with 9.0 long-term profitability 7.4 Streamlined execution 6.0 6.1 Resources concentrated where we see the greatest return
Slide 15: Unlocking further profitable growth
Unlocking further profitable growth Maximize the value of the growing Transform market access body of clinical evidence in insomnia Maximize the impact of emerging data Enhanced evidence package E.g., pediatric, menopause, nocturia data Negotiate improved access, optimize rebate strengthen different
Slide 16: The end-to-end DTP experience
The end-to-end DTP experience Patient experience Your doctor prescribed Your prescription is Your prescription is Your medication will Don't miss your Your appointment sent to pharmacy approved by be delivered to your Quviviq dose insurance and lowest home for free Your supply may be cost applied en
Slide 17: Leveraging deep expertise in orexin biology
“We are leveraging our deep expertise in orexin biology to maximize the therapeutic potential of this targeted system.” Martine Clozel, MD, Chief Scientific Officer & Head of Research 17 HY 2026 Financial Reporting | July 2026
Slide 18: Reinforcing differentiation through investigator sponsored studies
Reinforcing differentiation through investigator sponsored studies in insomnia and beyond 2026 2027 2028 2029 & Later Cognitive Performance Smoking Withdrawal Post-Traumatic Major Depressive Disorder Claudio Liguori Barbara Sorg, Stress Disorder Sara Lakis Granel University of Rome "Tor Vergata“ Leg
Slide 19: Daridorexant: A potential first-in-class option for pediatric insomnia
Daridorexant: A potential first-in-class option for pediatric insomnia Phase 2 dose-finding study Next steps • Efficacy and safety of three doses in pediatric patients aged 10 to <18. • Phase 2 dose-finding study is part of an agreed Pediatric Investigational Plan (PIP) • Enrolled patients with inso
Slide 20: Expand the long-term value of daridorexant beyond insomnia
Expand the long-term value of daridorexant beyond insomnia • The results from the pediatric study suggest that orexin signaling may play a broader role in children with neurodevelopmental disorders. • Detailed results will be shared at upcoming congresses and in peer- reviewed publications. • A clin
Slide 21: Advancing towards the launch of TRYVIO / JERAYGO
“We are advancing towards the launch of TRYVIO / JERAYGO – unlocking considerable value.” Dominique Le Terrier, Global Commercial Strategy & New Product Planning Aprocitentan is only available in the US under the tradename TRYVIO and is approved in the European Union, the UK, Switzerland, and Canada
Slide 22: TRYVIO/JERAYGO is uniquely placed in the treatment landscape
TRYVIO/JERAYGO is uniquely placed in the treatment landscape Distinct Pathway "Strong & Proven" efficacy profile 15.4 TRYVIO offers different mechanism mmHg Proven efficacy of 15.4 mmHg SBP of action, addressing an important reduction in patients receiving more pathway not offered by the RAAS than o
Slide 23: Capital-efficient commercialization model
Capital-efficient commercialization model Planning in parallel to ongoing partnering discussions Dedicated financing Co-promotion partner • An offer to commit financing to commercialize • Ongoing discussions with potential TRYVIO / JERAYGO in co-promotion partnership in co-promotion partners in the
Slide 24: Advancing an exciting pipeline
“We are advancing an exciting pipeline with creative and efficient programs.” Amer Joseph, MD, Chief Medical Officer & Head of Global Clinical Development 24 HY 2026 Financial Reporting | July 2026
Slide 25: Late-stage pipeline partnership with Viatris
Late-stage pipeline partnership with Viatris enables long-term value creation Selatogrel for acute Cenerimod for systemic lupus myocardial infarction erythematosus and lupus nephritis • A potent, fast-acting, reversible, and highly • A highly selective S1P1 receptor modulator selective P2Y12 inhibit
Slide 26: Lucerastat registration program for Fabry disease
Lucerastat registration program targeting monotherapy for all adult patients with Fabry disease Pivotal kidney biopsy study Renal function active-comparative (n≈16) study (n≈74) • Adult males with Fabry disease, • Adult patients with Fabry disease treatment-naïve or pseudo-naïve • Assessment of luce
Slide 27: CCR6 receptor antagonist proof-of-mechanism
CCR6 receptor antagonist proof-of-mechanism First-in-class, oral CCR6 antagonist targeting the Th17 axis with potential to redefine treatment by selectively reducing pathogenic immune cell migration while preserving systemic immune function Idorsia innovation Differentiator Development so far Phase
Slide 28: CXCR7 antagonist for progressive MS
CXCR7 antagonist for progressive MS First-in-class, brain-penetrating drug with unique potential to transform the treatment paradigm in MS by remyelination and restoration of neuronal function in addition to reducing neuroinflammation Patient population Idorsia innovation Differentiator Development
Slide 29: CXCR3 receptor antagonist for vitiligo
CXCR3 receptor antagonist for vitiligo A first-in-class targeted systemic therapy for effective and safer treatment of immuno-dermatology and autoimmune disorders such as vitiligo Patient population Idorsia innovation Differentiator Development so far Phase 2 study 34 million diagnosed First-in-clas
Slide 30: A pipeline of first- or best-in-class drugs
A pipeline of first- or best-in-class drugs Compound / Mechanism of action Phase 1 Phase 2 Phase 3 / Target indication Lucerastat Regulatory pathway to registration agreed with the FDA and in line with the feedback Oral potential for organ protection received from EMA. The program is expected to sup
Slide 31: Increasing our top-line growth is our priority
“Increasing our top-line growth is our priority.” Arno Groenewoud Chief Financial Officer 31 HY 2026 Financial Reporting | July 2026
Slide 32: We have increased sales significantly and kept OPEX stable
We have increased sales significantly and kept OPEX stable in CHF millions, Non-GAAP operating results* rounding differences may occur H1 2025 91 H1 2026 72 56 8 8 1 -6 -19 -15 -46 -45 -54 -101 -96 Product sales** Contract Cost of sales R&D SG&A Other income Non-GAAP revenue operating results * as o
Slide 33: Strong liquidity at the end of H1
Strong liquidity at the end of H1 in CHF millions, Liquidity rounding differences may occur 97 -96 147 35 6 189* 89 -45 -27 -117 89 1st tranche 2 tranche Warrants Repayment Liquidity nd Liquidity Product SG&A R&D Other** secured New exercise New Jan 1, sales OPEX OPEX Jun 30, term loan Money Money 2
Slide 34: No near-term cash relevant debt maturities
No near-term cash relevant debt maturities Indebtedness Nominal amount Maturity Comment as of June 30, 2026 (in CHF millions) Total 1,411 “Pay-as-you-can” debt notes secured with o Debt notes in Idorsia Investments SARL* 774 2048/2050 aprocitentan, selatogrel, and cenerimod Idorsia 637 Will convert
Slide 35: Continued QUVIVIQ sales growth with focused investments
Continued QUVIVIQ sales growth with focused investments Status: July 2026 CHF million Guidance 2026* Idorsia-led QUVIVIQ sales 200 Positive commercial Operating expenses -330 contribution and Non-GAAP EBIT -120 focused investment in US-GAAP EBIT -160 value-driving pipeline * Excluding unforeseen eve
Slide 36: Advancing four key drivers of growth
Advancing four key drivers of growth 1 Maximize the current QUVIVIQ® opportunity in insomnia 2 Expand the long-term value of daridorexant beyond insomnia 3 Unlock the value of TRYVIO / JERAYGO 4 Advance innovation and the pipeline Driving simultaneous initiatives to unlock substantial long-term valu
Slide 37: Looking forward to welcoming Roland Wandeler
Looking forward to welcoming Roland Wandeler CEO from Oct 1, 2026 37 HY 2026 Financial Reporting | July 2026
Slide 38: Advancing four key drivers of growth
Advancing four key drivers of growth 1 Maximize the current QUVIVIQ® opportunity in insomnia 2 Expand the long-term value of daridorexant beyond insomnia 3 Unlock the value of TRYVIO / JERAYGO 4 Advance innovation and the pipeline Driving simultaneous initiatives to unlock substantial long-term valu